VACVase Antibody (E-3): sc-514189

VACVase Antibody (E-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects VACVase protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-VACVase antibody (E-3) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VACVase protein, also known as valacyclovir hydrolase, BPHL (biphenyl hydrolase-like), or MCNAA, is a 291 amino acid enzyme belonging to the AB hydrolase superfamily, primarily expressed in the liver and kidney, with lower levels in the heart, intestine, and skeletal muscle. This serine hydrolase plays a crucial role in the hydrolytic activation of amino acid ester prodrugs, contributing to chemical detoxification processes within the body. VACVase contains a serine residue at its active site, enabling enzymatic hydrolysis and activation of compounds such as valacyclovir, an antiviral medication. VACVase is also expressed in various carcinoma cell lines, suggesting potential as a target for the activation of anticancer and antiviral prodrugs. Additionally, VACVase exists in two alternatively spliced isoforms, designated α and β, which may have distinct functional roles in different biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VACVase Antibody (E-3) References:

1. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase.  |  Kim, I., et al. 2003. J Biol Chem. 278: 25348-56. PMID: 12732646
2. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.  |  Kim, I., et al. 2004. Mol Pharm. 1: 117-27. PMID: 15832508
3. Structure and specificity of a human valacyclovir activating enzyme: a homology model of BPHL.  |  Kim, I., et al. 2004. Mol Pharm. 1: 434-46. PMID: 16028355
4. Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression.  |  Parrish, S. and Moss, B. 2006. J Virol. 80: 553-61. PMID: 16378957
5. Characterization of the vaccinia virus D10 decapping enzyme provides evidence for a two-metal-ion mechanism.  |  Soulière, MF., et al. 2009. Biochem J. 420: 27-35. PMID: 19210265
6. Insights into the molecular determinants involved in cap recognition by the vaccinia virus D10 decapping enzyme.  |  Soulière, MF., et al. 2010. Nucleic Acids Res. 38: 7599-610. PMID: 20639534
7. The D10 decapping enzyme of vaccinia virus contributes to decay of cellular and viral mRNAs and to virulence in mice.  |  Liu, SW., et al. 2014. J Virol. 88: 202-11. PMID: 24155373
8. Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping.  |  Alharbi, NK., et al. 2015. PLoS One. 10: e0127978. PMID: 26011541
9. alpha 1/alpha 2 Selectivity ratio in a series of agonists and their relation to pre/postsynaptic activity ratios.  |  Kobinger, W. and Pichler, L. 1983. Eur J Pharmacol. 91: 129-33. PMID: 6137391
10. New concepts on alpha-adrenoceptors in pharmacology.  |  Kobinger, W. 1984. J Pharmacol. 15 Suppl 1: 5-22. PMID: 6144815
11. Cloning and expression analysis of a novel human serine hydrolase with sequence similarity to prokaryotic enzymes involved in the degradation of aromatic compounds.  |  Puente, XS. and López-Otín, C. 1995. J Biol Chem. 270: 12926-32. PMID: 7759552
12. Structural characterization and chromosomal localization of the gene encoding human biphenyl hydrolase-related protein (BPHL).  |  Puente, XS., et al. 1998. Genomics. 51: 459-62. PMID: 9721218

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VACVase Antibody (E-3) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-VACVase Antibody (E-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VACVase Antibody (E-3) Specifications

Alternate Product Name: VACVase

Product Clone Name: E-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 158-230

Epitope Target: VACVase

Epitope Species: human

Product Reactivity/Detection: VACVase

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for VACVase Antibody (E-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin